Digestive Diseases and Sciences

, Volume 33, Issue 5, pp 619–624 | Cite as

The treatment of gastric ulcer with antisecretory drugs

Relationship of pharmacological effect to healing rates
  • C. W. Howden
  • D. B. Jones
  • K. E. Peace
  • D. W. Burget
  • R. H. Hunt
Point of View


Published clinical trials (N=56) of antisecretory drugs in the treatment of benign gastric ulcer were reviewed. Composite healing rates for various drug regimens were calculated using a method previously described for duodenal ulcer. Healing rates were compared with data on suppression of intragastric acidity to see if any relationship was evident. No significant correlations between the two existed, unless placebo data were included in the analysis. Correlations were stronger with suppression of total 24-hr rather than nocturnal acidity. Using Williams' method for assessing trends, it was found that an increase in antisecretory effect is not associated with a concomitant increase in healing rates. Duration of medical treatment is the single most important factor in healing of benign gastric ulcer; healing rates for all drug regimens and placebo show a consistent increase with prolongation of treatment.

Key words

gastric ulcer H2-receptor antagonists omeprazole meta-analysis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Grossman MI, Kirsner JB, Gillespie IE: Basal and histalogstimulated gastric secretion in control subjects and in patients with peptic ulcer or gastric cancer. Gastroenterology 45:14–26, 1963Google Scholar
  2. 2.
    Howden CW, Jones DB, Hunt RH: Nocturnal doses of H2 receptor antagonists for duodenal ulcer. Lancet 1:647–648, 1985Google Scholar
  3. 3.
    Jones DB, Howden CW, Burget DW, Kerr GD, Hunt RH: Acid suppression in duodenal ulcer: A meta-analysis to define optimal dosing with antisecretory drugs. Gut 28:1120–1127, 1987Google Scholar
  4. 4.
    Williams DA: A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics 27:103–117, 1971Google Scholar
  5. 5.
    Walt RP, Male PJ, Rawlings J, Hunt RH, Milton-Thompson GJ, Misiewicz JJ: Comparison of the effects of ranitidine, cimetidine and placebo on the 24-hour intragastric acidity and nocturnal acid secretion in patients with duodenal ulcer. Gut 22:49–54, 1981Google Scholar
  6. 6.
    Pounder RE, Williams JG, Hunt RH, Vincent SH, Milton-Thompson GJ, Misiewicz JJ: The effects of oral cimetidine on food-stimulated gastric acid secretion and 24 hour intragastric acidity.In Cimetidine. Proceedings of the Second International Symposium on Histamine H2-Receptor Antagonists. Amsterdam, Excerpta Medica, 189–206, 1977Google Scholar
  7. 7.
    Gledhill T, Buck M, Hunt RH: The effect of no treatment, cimetidine 1 g/day, cimetidine 2 g/day and cimetidine combined with atropine on nocturnal gastric secretion in cimetidine nonresponders. Gut 25:1211–1216, 1984Google Scholar
  8. 8.
    Gledhill T, Howard OM, Buck M, Paul A, Hunt RH: Single nocturnal doses of an H2-receptor antagonist for the treatment of duodenal ulcer. Gut 24:904–908, 1983Google Scholar
  9. 9.
    Gotthard R, Berstad A, Bodemar G, Norlander B, Walan A: Effect of cimetidine and oxmetidine on 24-h gastric acid and pepsin in patients. Scand J Gastroenterol 18:809–817, 1983Google Scholar
  10. 10.
    Dammann HG, Hoelzer P, Friedl W, Simon B: Gastrales Saureprofil uber 24 Stunden. Dsch Med Wochenschr 108:600–603, 1983Google Scholar
  11. 11.
    de Gara CJ, Burget DW, Silletti C, Hunt RH: Is daytime administration of H2 antagonists necessary for the control of acid and pepsin secretion? Am J Gastroenterol 79:819, 1984 (abstract)Google Scholar
  12. 12.
    Mahachai V, Walker K, Jamali F, Navert H, Cook D, Symes A, Thomson ABR: Comparative effects of two cimetidine regimens on 24-hour intragastric acidity in patients with asymptomatic duodenal ulcer. Clin Ther 6:259–281, 1984Google Scholar
  13. 13.
    Petersen WL, Barnett C, Feldman M, Richardson CT: Reduction of twenty-four-hour gastric acidity with combination drug therapy in patients with duodenal ulcer. Gastroenterology 77:1015–1020, 1979Google Scholar
  14. 14.
    Sharma BK, Walt RP, Pounder RE, Gomes MdeFA, Wood EC, Logan LH: Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 25:957–964, 1984Google Scholar
  15. 15.
    Graham DY, Akdamar K, Dyck WP, Engleert E, Strickland RG, Achord JL, Belsito AA, Vlahcevic R, Kornfield RN, Long WB, Sontag S, Agrawal NM: Healing of benign gastric ulcer: Comparison of cimetidine and placebo in the United States. Ann Intern Med 102:573–576, 1985Google Scholar
  16. 16.
    Howden CW, Jones DB, Hunt RH: Differences in placebo healing rates in duodenal and gastric ulcer: some implications for clinical trials. Acta Pharmacol Toxicol Suppl V:201, 1986 (presented at III World Conference on Clinical Pharmacology and Therapeutics, Stockholm, Sweden, July 1986)Google Scholar
  17. 17.
    Tatsuta M, Iishi H, Okuda S: Effects of cimetidine on the healing and recurrence of duodenal ulcers and gastric ulcers. Gut 27:1213–1218, 1986Google Scholar
  18. 18.
    Younan F, Pearson J, Allen A, Venables C: Changes in the structure of the mucous gel on the mucosal surface of the stomach in association with peptic ulcer disease. Gastroenterology 82:827–831, 1982Google Scholar
  19. 19.
    Cocking JB, MacCaig JN: Effect of low dosage of carbenoxolone sodium on gastric ulcer healing and acid secretion. Gut 10:219–225, 1969Google Scholar
  20. 20.
    Turpie AGG, Runcie J, Thomson TJ: Clinical trial of deglycyrrhizinized liquorice in gastric ulcer. Gut 10:299–302, 1969Google Scholar
  21. 21.
    Moshal MG: A double-blind gastroscopic study of a bismuth-peptide complex in gastric ulceration. South Afr Med J 48:1610–1611, 1974Google Scholar
  22. 22.
    Lahtinen J, Aukee S, Miettinen P, Poikolainen E, Paakkonen M, Sandstrom R: Sucralfate and cimetidine for gastric ulcer. Scand J Gastroenterol 18(suppl 83):49–51, 1983Google Scholar
  23. 23.
    Kauffman GL Jr, Grossman MI: Prostaglandin and cimetidine inhibition of the formation of ulcers produced by parenteral salicylates. Gastroenterology 75:1099–1102, 1978Google Scholar
  24. 24.
    Muller P, Fischer N, Kathern H, Simon B, Dammann G: Ranitidine and transmural potential difference. Results with sodium taurocholate. Dtsch Med Wochenschr 106:1577–1579, 1981Google Scholar

Copyright information

© Plenum Publishing Corporation 1988

Authors and Affiliations

  • C. W. Howden
    • 1
    • 2
    • 3
  • D. B. Jones
    • 1
    • 2
    • 3
  • K. E. Peace
    • 1
    • 2
    • 3
  • D. W. Burget
    • 1
    • 2
    • 3
  • R. H. Hunt
    • 1
    • 2
    • 3
  1. 1.Department of Materia MedicaUniversity of Glasgow, Stobhill General HospitalGlasgowScotland, UK
  2. 2.Division of GastroenterologyMcMaster UniversityHamiltonCanada
  3. 3.Department of BiostatisticsThe Medical College of VirginiaRichmond

Personalised recommendations